Retroperitoneal Haematoma Associated with Low Molecular Weight Heparin

A massive retroperitoneal hematoma during low-molecular-weight-heparin therapy.

A 75-year-old woman was admitted to our Cardiology Department with congestive heart failure. Oral anticoagulant therapy was discontinued to perform hemodynamic catheterization and low-molecular-weight-heparin (LMWH—subcutaneous enoxaparin 5700 IU BID) was started. The dosage of LMWH was assessed according to the patients constitution (weight 75 kg) and renal function index (eGFR 63 ml/min/1.73 ...

Low Molecular Weight Heparin Overdose: A 10 Year Case Series

  Background: Low molecular weight heparin (LMWH) is used for the treatment and prevention of coagulative disorders. Few patients receiving therapeutic doses of LMWH develop major hemorrhage. Currently there are few reports in the literature on acute overdose on adults.  In this study, clinical profile, treatment and outcome of 21 patients who acutely overdosed enoxaparin are described. Method...

Low molecular weight heparin.

Diffuse alveolar hemorrhage associated with low molecular weight heparin

Diffuse alveolar hemorrhage (DAH) has a varied etiology, including anticoagulation drugs. There is conflicting evidence whether low molecular weight heparin (LMWH) has a low risk of bleeding complications compared to unfractionated heparin. We report here a case of DAH in a 74-year-old woman who was administered enoxaparin, a LMWH, after bilateral total knee arthroplasty. Although congestive he...

Heparin and low-molecular-weight heparin.

Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have repl...